Literature DB >> 6987521

Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood.

S A Williams, S P Makker, J R Ingelfinger, W E Grupe.   

Abstract

We evaluated the long-term effects of a five to 15-week course of chlorambucil and prednisone in 59 children with idiopathic nephrotic syndrome who had previously received prednisone alone and had had frequent relapses or steroid dependency or resistance. By actuarial analysis of 65 courses of dual therapy followed up for one to 12 years (mean, 5.0), we found that 95 per cent of patients were in remission at one year and 85 per cent at four years. All but two had remissions lasting longer than those induced by steroids alone, and only eight others had one or more relapses after therapy. Life-table analysis of two dosage schedules of chlorambucil at four years showed that 91 per cent of patients on low doses and 80 per cent of those on high doses were still in remission. Although immediate complications were minimal, the potential for long-term toxicity still requires careful selection of patients who receive chlorambucil. Prolonged use of chlorambucil in daily doses above 0.3 mg per kilogram of body weight per day or cumulative doses above 14 mg per kilogram is no longer warranted. Measured in terms of both the immediate and long-term responses, chlorambucil appears to lower the frequency of relapses in idiopathic nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6987521     DOI: 10.1056/NEJM198004243021701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  15 in total

1.  High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease.

Authors:  H H Tessler; T Jennings
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 3.  Modern management of nephrotic syndrome.

Authors:  K K Kher; S P Makker; M Sweet
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

Review 4.  Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.

Authors:  Rebecca M Lombel; Debbie S Gipson; Elisabeth M Hodson
Journal:  Pediatr Nephrol       Date:  2012-10-03       Impact factor: 3.714

5.  Evaluation of chlorambucil therapy in steroid-dependent and cyclophosphamide-resistant children with nephrosis.

Authors:  A Y Elzouki; O P Jaiswal
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

6.  Chlorambucil central nervous toxicity: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome.

Authors:  F Ichida; T Konishi; R Asada; M Yamatani; M Konda; M Tani; T Tanizawa; Y Suzuki; T Okada; S Kyotani
Journal:  Eur J Pediatr       Date:  1985-09       Impact factor: 3.183

7.  Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors: 
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

8.  Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  J Brodehl; M Brandis; U Helmchen; P F Hoyer; R Burghard; J H Ehrich; R B Zimmerhackl; W Klein; K Wonigeit
Journal:  Klin Wochenschr       Date:  1988-11-15

9.  Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology.

Authors:  P Niaudet
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

10.  Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome.

Authors:  D P Jones; F B Stapleton; S Roy; R J Wyatt
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.